Environmental Factors for Epstein-Barr Virus Reactivation in a High-Risk Area of Nasopharyngeal Carcinoma: A Population-Based Study.

EBV reactivation Epstein-Barr virus environmental factors nasopharyngeal carcinoma risk factor serology

Journal

Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045

Informations de publication

Date de publication:
May 2022
Historique:
received: 08 12 2021
accepted: 14 03 2022
entrez: 22 4 2022
pubmed: 23 4 2022
medline: 23 4 2022
Statut: epublish

Résumé

Epstein-Barr virus (EBV) reactivation from latent to lytic infection has been considered as a key step in nasopharyngeal carcinoma oncogenesis. However, epidemiological evidence regarding environmental risk factors for EBV reactivation on a population level remains largely lacking. We enrolled 1916 randomly selected adults from the general population of Guangdong and Guangxi, China, from 2010 to 2014. Information on environmental factors was collected via a structured interview. Serum immunoglobulin A antibodies against EBV viral capsid antigen and nuclear antigen 1 were measured by enzyme-linked immunosorbent assay to evaluate EBV reactivation status. We used logistic regression to calculate odds ratios (ORs) with 95% confidence intervals (CIs) for the associations of EBV reactivation with various environmental factors. No associations were observed between EBV reactivation and extensive environmental factors, including alcohol or tea drinking, a history of chronic ear/nose/throat diseases, use of medications or herbs, consumption of salted fish or preserved foods, oral hygiene, sibship structure, and various residential and occupational exposures. Only cigarette smoking was associated with EBV reactivation (current smokers vs never smokers; OR = 1.37; 95% CI = 1.02-1.83), with positive exposure-response trends with increasing intensity, duration, and pack-years of smoking. Consistent with previous studies, we found an association between cigarette smoking and EBV reactivation. Other examined exposures were not associated with EBV reactivation. These null results could suggest either more complex interactions between exposures and EBV reactivation or a predominant role of host and/or viral genetic variation.

Sections du résumé

Background UNASSIGNED
Epstein-Barr virus (EBV) reactivation from latent to lytic infection has been considered as a key step in nasopharyngeal carcinoma oncogenesis. However, epidemiological evidence regarding environmental risk factors for EBV reactivation on a population level remains largely lacking.
Methods UNASSIGNED
We enrolled 1916 randomly selected adults from the general population of Guangdong and Guangxi, China, from 2010 to 2014. Information on environmental factors was collected via a structured interview. Serum immunoglobulin A antibodies against EBV viral capsid antigen and nuclear antigen 1 were measured by enzyme-linked immunosorbent assay to evaluate EBV reactivation status. We used logistic regression to calculate odds ratios (ORs) with 95% confidence intervals (CIs) for the associations of EBV reactivation with various environmental factors.
Results UNASSIGNED
No associations were observed between EBV reactivation and extensive environmental factors, including alcohol or tea drinking, a history of chronic ear/nose/throat diseases, use of medications or herbs, consumption of salted fish or preserved foods, oral hygiene, sibship structure, and various residential and occupational exposures. Only cigarette smoking was associated with EBV reactivation (current smokers vs never smokers; OR = 1.37; 95% CI = 1.02-1.83), with positive exposure-response trends with increasing intensity, duration, and pack-years of smoking.
Conclusions UNASSIGNED
Consistent with previous studies, we found an association between cigarette smoking and EBV reactivation. Other examined exposures were not associated with EBV reactivation. These null results could suggest either more complex interactions between exposures and EBV reactivation or a predominant role of host and/or viral genetic variation.

Identifiants

DOI: 10.1093/ofid/ofac128 PMID: 35450082 PMC: PMC9017372
pubmed: 35450082
doi: 10.1093/ofid/ofac128
pii: ofac128
pmc: PMC9017372
doi:

Types de publication

Journal Article

Langues

eng

Pagination

ofac128

Subventions

Organisme : NCI NIH HHS
ID : R01 CA115873
Pays : United States

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Références

Int J Cancer. 2020 Dec 7;:
pubmed: 33285002
BMC Cancer. 2018 Feb 14;18(1):190
pubmed: 29444646
Int J Cancer. 2009 May 1;124(9):2016-25
pubmed: 19132751
Sci Rep. 2021 Feb 25;11(1):4586
pubmed: 33633271
Environ Int. 2021 Jun;151:106455
pubmed: 33652252
Proc Natl Acad Sci U S A. 2006 May 2;103(18):7065-70
pubmed: 16606841
Open Forum Infect Dis. 2020 Sep 12;7(10):ofaa426
pubmed: 33134413
PLoS One. 2011 Apr 22;6(4):e19100
pubmed: 21544243
Nat Genet. 2019 Jul;51(7):1131-1136
pubmed: 31209392
Semin Cancer Biol. 2002 Dec;12(6):431-41
pubmed: 12450729
Crit Rev Oncol Hematol. 2000 Apr;34(1):27-53
pubmed: 10781747
Am J Epidemiol. 2013 Feb 1;177(3):242-50
pubmed: 23255783
J Natl Cancer Inst. 2012 Sep 19;104(18):1396-410
pubmed: 22972969
Microorganisms. 2020 Nov 19;8(11):
pubmed: 33228078
Cancer. 2021 Aug 1;127(15):2724-2735
pubmed: 33823062
Lancet. 2019 Jul 6;394(10192):64-80
pubmed: 31178151
Virus Evol. 2021 Jun 04;7(1):veab010
pubmed: 34567789
Cancer Epidemiol Biomarkers Prev. 2021 Jun;30(6):1035-1047
pubmed: 33849968
Philos Trans R Soc Lond B Biol Sci. 2017 Oct 19;372(1732):
pubmed: 28893937
Int J Cancer. 2012 Jul 15;131(2):406-16
pubmed: 21866545
Immunity. 2002 May;16(5):745-54
pubmed: 12049725
Ann Oncol. 2019 Oct 1;30(10):1630-1637
pubmed: 31373615
Oncotarget. 2017 Jul 29;8(50):87073-87085
pubmed: 29152064
Cancer Med. 2019 May;8(5):2561-2571
pubmed: 30843658
Expert Rev Mol Med. 2007 May 04;9(12):1-24
pubmed: 17477889
Biomed Environ Sci. 1994 Mar;7(1):50-5
pubmed: 8024719
J Virol. 2014 Jul;88(14):8028-44
pubmed: 24807711
Curr Top Microbiol Immunol. 2015;391:289-323
pubmed: 26428379
Semin Cancer Biol. 2012 Apr;22(2):117-26
pubmed: 22311401
Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1765-77
pubmed: 17035381
Nat Rev Cancer. 2016 Dec;16(12):789-802
pubmed: 27687982
Br J Cancer. 2007 Feb 26;96(4):623-30
pubmed: 17285127
Exp Mol Med. 2015 Jan 23;47:e130
pubmed: 25613727
EBioMedicine. 2018 Apr;30:184-191
pubmed: 29606628
N Engl J Med. 2001 Dec 27;345(26):1877-82
pubmed: 11756578
Cancer Med. 2020 Mar;9(5):1867-1876
pubmed: 31925935

Auteurs

Yufeng Chen (Y)

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.

Ellen T Chang (ET)

Exponent, Inc., Center for Health Sciences, Menlo Park, California, USA.
ORCID: 0000-0002-7169-157X

Qing Liu (Q)

Department of Cancer Prevention Center, Sun Yat-sen University Cancer Center, Guangzhou, China.
State Key Laboratory of Oncology in South China & Collaborative Innovation Center for Cancer Medicine & Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.

Yonglin Cai (Y)

Department of Clinical Laboratory, Wuzhou Red Cross Hospital, Wuzhou, China.
Wuzhou Health System Key Laboratory for Nasopharyngeal Carcinoma Etiology and Molecular Mechanism, Wuzhou, China.

Zhe Zhang (Z)

Department of Otolaryngology-Head & Neck Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Key Laboratory of High-Incidence-Tumor Prevention & Treatment (Guangxi Medical University), Ministry of Education, Nanning, China.

Guomin Chen (G)

State Key Laboratory for Infectious Diseases Prevention and Control, Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.

Qi-Hong Huang (QH)

Sihui Cancer Institute, Sihui, China.

Shang-Hang Xie (SH)

Department of Cancer Prevention Center, Sun Yat-sen University Cancer Center, Guangzhou, China.
State Key Laboratory of Oncology in South China & Collaborative Innovation Center for Cancer Medicine & Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.

Su-Mei Cao (SM)

Department of Cancer Prevention Center, Sun Yat-sen University Cancer Center, Guangzhou, China.
State Key Laboratory of Oncology in South China & Collaborative Innovation Center for Cancer Medicine & Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.

Wei-Hua Jia (WH)

State Key Laboratory of Oncology in South China & Collaborative Innovation Center for Cancer Medicine & Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.
ORCID: 0000-0002-0528-8715

Yuming Zheng (Y)

Department of Clinical Laboratory, Wuzhou Red Cross Hospital, Wuzhou, China.
Wuzhou Health System Key Laboratory for Nasopharyngeal Carcinoma Etiology and Molecular Mechanism, Wuzhou, China.

Yancheng Li (Y)

Cangwu Institute for Nasopharyngeal Carcinoma Control and Prevention, Wuzhou, China.

Longde Lin (L)

Key Laboratory of High-Incidence-Tumor Prevention & Treatment (Guangxi Medical University), Ministry of Education, Nanning, China.

Ingemar Ernberg (I)

Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
ORCID: 0000-0001-6518-1648

Guangwu Huang (G)

Department of Otolaryngology-Head & Neck Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Key Laboratory of High-Incidence-Tumor Prevention & Treatment (Guangxi Medical University), Ministry of Education, Nanning, China.
ORCID: 0000-0002-7376-5691

Yi-Xin Zeng (YX)

State Key Laboratory of Oncology in South China & Collaborative Innovation Center for Cancer Medicine & Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.
Beijing Hospital, Beijing, China.

Hans-Olov Adami (HO)

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Clinical Effectiveness Group, Institute of Health and Society, University of Oslo, Oslo, Norway.

Weimin Ye (W)

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Department of Epidemiology and Health Statistics & Key Laboratory of Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, Fuzhou, China.

Classifications MeSH